Cargando…

Analysis of Vδ1 T cells in clinical grade melanoma-infiltrating lymphocytes

γδ T cells, including Vδ1 and Vδ2 T cells, can recognize tumor-associated ligands neglected by conventional αβ T cells in a MHC-independent manner. Little is known regarding the anticancer potential and the possibility to isolate and expand Vδ1 T cells to therapeutically relevant numbers. In this st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Donia, Marco, Ellebaek, Eva, Andersen, Mads Hald, Straten, Per thor, Svane, Inge Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2012
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518502/ https://www.ncbi.nlm.nih.gov/pubmed/23243593 http://dx.doi.org/10.4161/onci.21659

Ejemplares similares

Adoptive cell therapy with tumor infiltrating lymphocytes and intermediate dose IL-2 for metastatic melanoma
por: Andersen, Rikke, et al.
Publicado: (2014)

Characterization of Ex Vivo Expanded Tumor Infiltrating Lymphocytes from Patients with Malignant Melanoma for Clinical Application
por: Junker, Niels, et al.
Publicado: (2011)

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients
por: Ellebaek, Eva, et al.
Publicado: (2012)

Therapeutic Cancer Vaccines in Combination with Conventional Therapy
por: Andersen, Mads Hald, et al.
Publicado: (2010)

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
por: Borch, Troels Holz, et al.
Publicado: (2014)

BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer
por: Donia, Marco, et al.
Publicado: (2012)

Effects of Ipilimumab on expanded tumor infiltrating lymphocytes in patients with stage IV malignant melanoma
por: Bjørn, Jon, et al.
Publicado: (2013)

Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
por: Borch, Troels Holz, et al.
Publicado: (2020)

Natural CD4(+) T-Cell Responses against Indoleamine 2,3-Dioxygenase
por: Munir, Shamaila, et al.
Publicado: (2012)

Characterization of Spontaneous Immune Responses against Long Peptides Derived from Bcl-X(L) in Cancer Patients Using Elispot
por: Larsen, Stine Kiaer, et al.
Publicado: (2012)

S76. Adoptive cell therapy of melanoma with autologous tumour infiltrating lymphocytes
por: Svane, I, et al.
Publicado: (2014)

Polyfunctional incompletely differentiated CD8+ T cells accumulates after adoptive transfer of tumor-infiltrating lymphocytes and establish immunological memory in patients with metastatic melanoma
por: Donia, Marco, et al.
Publicado: (2015)

Cancer treatment: the combination of vaccination with other therapies
por: Andersen, Mads Hald, et al.
Publicado: (2008)

Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients
por: Iversen, Trine Zeeberg, et al.
Publicado: (2013)

Improved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma
por: Soerensen, Anne Vest, et al.
Publicado: (2020)

A Potential Role of Indoleamine 2,3-Dioxygenase–Specific T cells in Leishmania Vaccination
por: Straten, Per thor, et al.
Publicado: (2011)

The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens
por: thor Straten, Per, et al.
Publicado: (2010)

Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors
por: Andersen, Rikke Sick, et al.
Publicado: (2010)

Broadening the repertoire of melanoma-associated T-cell epitopes
por: Frøsig, Thomas Mørch, et al.
Publicado: (2015)

Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes
por: Hulen, Thomas Morgan, et al.
Publicado: (2023)

Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
por: Lorentzen, Cathrine Lund, et al.
Publicado: (2023)

T-cell clonotypes in cancer
por: thor Straten, Per, et al.
Publicado: (2004)

HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer
por: Andersen, Mads Hald, et al.
Publicado: (2006)

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2021)

Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2022)

Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy
por: Chamberlain, Christopher Aled, et al.
Publicado: (2022)

Collagen density regulates the activity of tumor-infiltrating T cells
por: Kuczek, Dorota E., et al.
Publicado: (2019)

The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4(+) T cells
por: Munir, Shamaila, et al.
Publicado: (2013)

Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an HLA-A2-restricted epitope derived from indoleamine 2,3 dioxygenase
por: Iversen, Trine Z, et al.
Publicado: (2013)

Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma
por: Bol, Kalijn Fredrike, et al.
Publicado: (2019)

The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase
por: Sørensen, Rikke Bæk, et al.
Publicado: (2009)

Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8(+) T Cells in Non-Melanoma Cancers Compared to Melanoma
por: Gokuldass, Aishwarya, et al.
Publicado: (2020)

Exploitation of gamma delta T cells in cancer immunotherapy as combined antigen-presenters and cancer cell killers
por: Holmen Olofsson, Gitte, et al.
Publicado: (2014)

CTLA-4 blockade boosts the expansion of tumor-reactive CD8(+) tumor-infiltrating lymphocytes in ovarian cancer
por: Friese, Christina, et al.
Publicado: (2020)

Neoantigen-reactive CD8(+) T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma
por: Kristensen, Nikolaj Pagh, et al.
Publicado: (2022)

Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes
por: Sittig, Simone P, et al.
Publicado: (2013)

Association of a functional Indoleamine 2,3-dioxygenase 2 genotype with specific immune responses
por: Køllgaard, Tania, et al.
Publicado: (2012)

Pre-Vaccination Frequencies of Th17 Cells Correlate with Vaccine-Induced T-Cell Responses to Survivin-Derived Peptide Epitopes
por: Køllgaard, Tania, et al.
Publicado: (2015)

Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment
por: Hadrup, Sine, et al.
Publicado: (2012)

Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma
por: Bjoern, Jon, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_k92fcrvb4uso8ojcd92ne16i4o